Kent Matsuda, MD
Internal Medicine · Santa Rosa, CANPI 1073531117
Payments from drug & device makers
Across 408 payments — averaging $24.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$2K
- Lilly USA, LLC$779
- Radius Health, Inc.$773
- Bayer$712
- Boehringer Ingelheim$569
- plus $3K from 28 others
What the payments were for
- Food & beverage$9,46296%
- Education$150%
- Other$3724%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 82 | $1,906 |
| AbbVie(2 entities) | 72 | $1,653 |
| Lilly USA, LLC | 33 | $779 |
| Radius Health, Inc. | 33 | $773 |
| Bayer | 25 | $712 |
| Boehringer Ingelheim | 28 | $569 |
| Collegium Pharmaceutical, Inc. | 21 | $419 |
| Astellas Pharma US Inc | 17 | $371 |
| GSK | 17 | $358 |
| Gilead | 5 | $337 |
| Pfizer | 14 | $276 |
| Baxter Healthcare | 1 | $186 |
| Welch Allyn | 1 | $186 |
| AstraZeneca | 4 | $166 |
| Merck | 8 | $152 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $129 |
| Biogen | 6 | $126 |
| Amgen | 5 | $111 |
| Phathom Pharmaceuticals, Inc. | 1 | $108 |
| Johnson & Johnson | 3 | $78 |
| Biodelivery Sciences International, Inc. | 4 | $61 |
| Novartis | 3 | $60 |
| Biohaven Pharmaceuticals, Inc. | 2 | $52 |
| Neurocrine Biosciences, Inc. | 2 | $49 |
| Esperion Therapeutics, Inc. | 3 | $46 |
| Exact Sciences | 1 | $27 |
| Sumitomo Pharma America, Inc. | 3 | $25 |
| Genentech USA, Inc. | 1 | $23 |
| Verity Pharmaceuticals Inc. | 1 | $22 |
| Sandoz | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Edwards Lifesciences | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,849 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 149 | $107,768 |
| OxycontinOxycodone Hcl | 35 | $78,480 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 13 | $45,220 |
| XareltoRivaroxaban | 33 | $33,714 |
| JardianceEmpagliflozin | 26 | $22,757 |
| OzempicSemaglutide | 12 | $10,418 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $7,286 |
| ErtapenemErtapenem Sodium | 32 | $7,126 |
| Pregabalin | 53 | $6,994 |
| Buprenorphine | 24 | $4,907 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,706 |
| Fentanyl | 30 | $4,309 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $4,151 |
| Levothyroxine Sodium | 181 | $3,978 |
| Morphine Sulfate ErMorphine Sulfate | 39 | $3,929 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $276 | $107,768149 claims |
| Johnson & JohnsonXarelto | $78 | $33,71433 claims |
| Boehringer IngelheimJardiance | $569 | $22,75726 claims |
| Novo NordiskOzempic | $1,906 | $10,41812 claims |
| AbbVieNamzaric, Synthroid | $1,653 | $9,26351 claims |
| GSKBreo Ellipta, Incruse Ellipta | $358 | $8,85722 claims |
| Lilly USA, LLCOlanzapine | $779 | $1,44643 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Santa Rosa
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.